Paroxysmal nocturnal hemoglobinuria (PNH) – the rare blood disorder characterized by premature destruction of red blood cells – found itself in the spotlight, as did shares of Omeros Corp. (NASDAQ:OMER), which closed Oct. 15 at $10.42, up $6.32, or 154%, on word of an asset purchase and license agreement with Novo Nordisk A/S for zaltenibart (formerly OMS-906).
Hinge Bio Inc. has obtained IND approval from the FDA to initiate a phase I study of HB-2198 in patients with the B cell-mediated autoimmune diseases systemic lupus erythematosus (SLE) and lupus nephritis. The trial is expected to open this quarter.
Climb Bio Inc. has announced results from a completed nonhuman primate (NHP) study of CLYM-116, an anti-APRIL monoclonal antibody (mAb) in development for IgA nephropathy.
Tuojie Biotech (Shanghai) Co. Ltd. has described apelin receptor (APLNR) agonists reported to be useful for the treatment of neurological disorders, cardiovascular disorders, obesity, diabetes, chronic kidney diseases and diabetic nephropathy.
Autosomal dominant polycystic kidney disease (PKD) is a chronic and debilitating condition affecting over 12 million patients worldwide. PKD arises from mutations in the polycystin-1 (PC1) or PC2 genes. PKD is characterized by the formation of fluid-filled cysts in the kidneys, leading to inflammation, fibrosis and organ damage, ultimately resulting in renal failure.
Maze Therapeutics Inc. CEO Jason Coloma said the latest phase I results with MZE-782, a prospect for phenylketonuria (PKU) as well as chronic kidney disease (CKD), bolster the firm’s “conviction to move into phase II” next year in both indications.
Rapafusyn Pharmaceuticals Inc. has closed a series A financing round raising a total of $44 million to advance its Rapaglues non-degrading molecular glue drug discovery platform and its pipeline in oncology, immunology, renal and pain disease areas.
The recombinant fusion protein drug telitacicept from Remegen Co. Ltd. and Vor Bio Inc. has notched a phase III win in treating adults with IgA nephropathy. The clinical trial of the fusion protein hit the primary endpoint, reducing proteinuria, too much protein in patients’ urine, in stage A of the study in China.
Diabetic nephropathy (DN) is a complication of diabetes and a leading cause of end-stage renal disease globally, with a rate of about 40% in patients with diabetes and limited access to therapeutic options.
The recombinant fusion protein drug telitacicept from Remegen Co. Ltd. and Vor Bio Inc. has notched a phase III win in treating adults with IgA nephropathy. The clinical trial of the fusion protein hit the primary endpoint, reducing proteinuria, too much protein in patients’ urine, in stage A of the study in China.
RSS
